2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

SCREENING
FDA Approves SimpleScreen CRC Blood Test for Average-Risk Adults
The FDA has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in adults aged 45 years and older who are at average risk, based on data from the PREEMPT CRC trial. (The ASCO Post)
RESEARCH
Circulating Tumor DNA May Guide Adjuvant Chemotherapy After Liver Metastasis Surgery
Circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer and liver metastases who are most likely to benefit from adjuvant chemotherapy after surgery, according to overall survival findings from the phase II GALAXY study presented at ESMO GI Congress 2026. (The ASCO Post)
SCREENING
Environmental Impact Study Compares Carbon Footprint of CRC Screening Tests
A life cycle assessment at UCSF compared the environmental impacts of three CRC screening strategies—annual faecal immunochemical tests, CT colonographies every 5 years, or colonoscopies every 10 years—measuring global warming potential and damage to human health. (BMJ Public Health)
LIVING WITH CRC
Most Patients Lack Documented Surveillance Plan After Polyp Removal
A retrospective audit at King Saud University Medical City found that 74.9% of patients who underwent screening colonoscopy with polypectomy had no documented surveillance plan, and among those with a plan, only 14.0% overall were guideline-concordant. (J Taibah Univ Med Sci)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Salvage Pancreaticoduodenectomy for KRAS G12D Colon Cancer Recurrence
A 66-year-old man with T4bN0M0 ascending colon cancer harboring a KRAS G12D mutation underwent salvage pancreaticoduodenectomy for localized recurrence after initial resection and adjuvant chemotherapy. (Clin J Gastroenterol)
Lynch Syndrome Study Finds No Racial Differences in Adenoma or SSL Occurrence
A retrospective cohort of 187 Lynch syndrome patients found that at first colonoscopy, 23% had sessile serrated lesions, 8.6% had adenomas, and 17.1% had CRC, with no difference by race or socioeconomic status; MSH6 was the most common MMR subtype at 31.0%. (Gastro Hep Adv)

These updates reflect ongoing efforts to improve screening access, refine surveillance practices, and personalize care based on molecular profiles.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues